In a meta-analysis pooling data from 2 randomized controlled phase 3 trials conducted in the Systematic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE, MRC-PR08), Attard et al. investigated the addition of abiraterone and prednisone with or without enzalutamide to ADT for nodal positive non-metastatic PCa or localized PCa with at least two high-risk features, which were defined as tumor stage T3 or T4, Gleason sum score of 8–10 and PSA concentration >40 ng/ml [13]. Here, KLK3 is linked to prostate carcinoma.